Diabetes Market Research Reports & Industry Analysis

The notion “diabetes” refers to a disease impacting the body’s ability to produce/use insulin. At present, more than 365 million people suffer from the disease worldwide. By 2030, the figure may reach 550 million. Inappropriate eating habits combined with a sedentary lifestyle, growth of the diabetic population and an increase in the number of obesity cases are amid the main factors contributing to the diabetes market growth. The list of the products available on the market is extensive: continuous blood glucose meters, anti-diabetic drugs, insulin and insulin pumps, artificial pancreas devices, etc.

Evaluated at over USD 19.8 billion, North America represents the top market, while Europe acts as the second largest player. The global diabetes market is expected to be at approximately USD 100 billion in 2018, showing a twofold increase if compared to 2011.

The Catalogue includes research reports dedicated to the diabetes market. The studies describe past and current industry trends, disclose data on the market competition and profile top industry behemoths. Information on the upcoming market events, industry growth drivers and hindrances can be found in the reports, too. Besides, the research reports contain evaluation of the actual economic situation, analyses of the market prospects.

Found 155 publications
PharmaPoint: Type 2 Diabetes - Global Drug Forecast and Market Analysis to 2022 - Event-Driven Update US$ 9,995.00

... the use of combination therapies and novel branded drugs. With the recent therapeutic guidelines putting emphasis on a patient-tailored approach in treating type 2 diabetes, pharmaceutical companies will achieve considerable success with their me-too drugs. In the future, companies will have to shift their ...

Jan, 2014 465 pages
PharmaPoint: Microvascular Complications of Diabetes - Global Drug Forecast and Market Analysis to 2022 US$ 9,995.00

... ) and due to the uptake of one novel branded drug for diabetic nephropathy. Highlights Key Questions Answered None of the current therapies ... but potentially very lucrative market? The diagnosed prevalence of microvascular complications of diabetes in the world dangerously increased in the past 10 years and ...

Dec, 2013 367 pages
PharmaPoint: Microvascular Complications of Diabetes - US Drug Forecast and Market Analysis to 2022 US$ 4,995.00

PharmaPoint: Microvascular Complications of Diabetes - US Drug Forecast and Market Analysis to 2022 Summary The entire market for microvascular complications of diabetes (MCD) – diabetic nephropathy, retinopathy, and neuropathy – is facing an extremely high level of unmet need across the 7MM (US, 5EU and ...

Dec, 2013 150 pages
PharmaPoint: Microvascular Complications of Diabetes - UK Drug Forecast and Market Analysis to 2022 US$ 4,995.00

PharmaPoint: Microvascular Complications of Diabetes - UK Drug Forecast and Market Analysis to 2022 Summary The entire market for microvascular complications of diabetes (MCD) – diabetic nephropathy, retinopathy, and neuropathy – is facing an extremely high level of unmet need across the 7MM (US, 5EU and ...

Dec, 2013 143 pages
PharmaPoint: Microvascular Complications of Diabetes - Spain Drug Forecast and Market Analysis to 2022 US$ 4,995.00

PharmaPoint: Microvascular Complications of Diabetes - Spain Drug Forecast and Market Analysis to 2022 Summary The entire market for microvascular complications of diabetes (MCD) – diabetic nephropathy, retinopathy, and neuropathy – is facing an extremely high level of unmet need across the 7MM (US, 5EU ...

Dec, 2013 143 pages
PharmaPoint: Microvascular Complications of Diabetes - Japan Drug Forecast and Market Analysis to 2022 US$ 4,995.00

PharmaPoint: Microvascular Complications of Diabetes - Japan Drug Forecast and Market Analysis to 2022 Summary The entire market for microvascular complications of diabetes ... . The uptake of Eylea, which will receive additional approval for diabetic retinopathy/DME, will further drive sales in the MCD market ...

Dec, 2013 145 pages
PharmaPoint: Microvascular Complications of Diabetes - Italy Drug Forecast and Market Analysis to 2022 US$ 4,995.00

PharmaPoint: Microvascular Complications of Diabetes - Italy Drug Forecast and Market Analysis to 2022 Summary The entire market for microvascular complications of diabetes (MCD) – diabetic nephropathy, retinopathy, and neuropathy – is facing an extremely high level of unmet need across the 7MM (US, 5EU ...

Dec, 2013 144 pages
PharmaPoint: Microvascular Complications of Diabetes - Germany Drug Forecast and Market Analysis to 2022 US$ 4,995.00

PharmaPoint: Microvascular Complications of Diabetes - Germany Drug Forecast and Market Analysis to 2022 Summary The entire market for microvascular complications of diabetes (MCD) – diabetic nephropathy, retinopathy, and neuropathy – is facing an extremely high level of unmet need across the 7MM (US, 5EU ...

Dec, 2013 144 pages
PharmaPoint: Microvascular Complications of Diabetes - France Drug Forecast and Market Analysis to 2022 US$ 4,995.00

PharmaPoint: Microvascular Complications of Diabetes - France Drug Forecast and Market Analysis to 2022 Summary The entire market for microvascular complications of diabetes (MCD) – diabetic nephropathy, retinopathy, and neuropathy – is facing an extremely high level of unmet need across the 7MM (US, 5EU ...

Dec, 2013 145 pages
Ranirestat (Microvascular Complications of Diabetes) - Forecast and Market Analysis to 2022 US$ 3,495.00

Ranirestat (Microvascular Complications of Diabetes) - Forecast and Market Analysis to 2022 Summary The entire market for microvascular complications of diabetes (MCD) – diabetic nephropathy, retinopathy, and neuropathy – is facing an extremely high level of unmet need across the 7MM (US, 5EU and Japan). ...

Dec, 2013 73 pages
PharmaPoint: Microvascular Complications of Diabetes - Current and Future Players US$ 2,995.00

... Players Summary GlobalData has released its pharma report, “PharmaPoint: Microvascular Complications of Diabetes - Current and Future Players”. The report is a vital ... , future market scenario and company analysis Reasons to buy Gain a high level view of the trends shaping and driving the Microvascular ...

Dec, 2013 51 pages
Optina (Microvascular Complications of Diabetes) - Forecast and Market Analysis to 2022 US$ 3,495.00

Optina (Microvascular Complications of Diabetes) - Forecast and Market Analysis to 2022 Summary The entire market for microvascular complications of diabetes (MCD) – diabetic ... analysis. Sales forecast for Optina for the top seven countries from 2012 to 2022. Sales information covered for the US, France, ...

Dec, 2013 74 pages
Lucentis (Microvascular Complications of Diabetes) - Forecast and Market Analysis to 2022 US$ 3,495.00

Lucentis (Microvascular Complications of Diabetes) - Forecast and Market Analysis to 2022 Summary The entire market for microvascular complications of diabetes (MCD) – diabetic nephropathy, retinopathy, and neuropathy – is facing an extremely high level of unmet need across the 7MM (US, 5EU and Japan). ...

Dec, 2013 59 pages
Eylea (Microvascular Complications of Diabetes) - Forecast and Market Analysis to 2022 US$ 3,495.00

Eylea (Microvascular Complications of Diabetes) - Forecast and Market Analysis to 2022 Summary The entire market for microvascular complications of diabetes (MCD) – diabetic ... analysis. Sales forecast for Eylea for the top seven countries from 2012 to 2022. Sales information covered for the US, France, ...

Dec, 2013 75 pages
Avastin (Microvascular Complications of Diabetes) - Forecast and Market Analysis to 2022 US$ 3,495.00

Avastin (Microvascular Complications of Diabetes) - Forecast and Market Analysis to 2022 Summary The entire market for microvascular complications of diabetes (MCD) – diabetic ... analysis. Sales forecast for Avastin for the top seven countries from 2012 to 2022. Sales information covered for the US, France ...

Dec, 2013 58 pages
Atrasentan (Microvascular Complications of Diabetes) - Forecast and Market Analysis to 2022 US$ 3,495.00

Atrasentan (Microvascular Complications of Diabetes) - Forecast and Market Analysis to 2022 Summary The entire market for microvascular complications of diabetes (MCD) – diabetic nephropathy, retinopathy, and neuropathy – is facing an extremely high level of unmet need across the 7MM (US, 5EU and Japan). ...

Dec, 2013 74 pages
UAE Diabetes Market Opportunity Analysis 2018 US$ 600.00

... the local domestic production sector, but the major hurdle is that UAE is not well equipped and does not posses the required capability ... country is thus a net importer of devices used for diabetes care. “UAE Diabetes Market Opportunity Analysis 2018” gives comprehensive insight on following aspects related ...

Jan, 2014 33 pages
EpiCast Report: Diabetic Neuropathy - Epidemiology Forecast to 2022 US$ 3,995.00

EpiCast Report: Diabetic Neuropathy - Epidemiology Forecast to 2022 Summary Diabetic neuropathy affects an estimated 50% of patients with diabetes and is one of the leading ... plans. Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for diabetic ...

Nov, 2013 45 pages
Tresiba (Type 2 Diabetes) - Forecast and Market Analysis to 2022 US$ 3,495.00

... and Market Analysis to 2022 Summary GlobalData has released its new report, “Tresiba (Type 2 Diabetes) - Forecast and Market Analysis to 2022”. The type ... ’ efforts to delay disease progression and reduce the costly burden of diabetic complications through the use of combination therapies and novel branded ...

Jul, 2013 46 pages
Trelagliptin (Type 2 Diabetes) - Forecast and Market Analysis to 2022 US$ 3,495.00

... and Market Analysis to 2022 Summary GlobalData has released its new report, “Trelagliptin (Type 2 Diabetes) - Forecast and Market Analysis to 2022”. The ... ’ efforts to delay disease progression and reduce the costly burden of diabetic complications through the use of combination therapies and novel branded ...

Jul, 2013 60 pages
Tradjenta (Type 2 Diabetes) - Forecast and Market Analysis to 2022 US$ 3,495.00

... and Market Analysis to 2022 Summary GlobalData has released its new report, “Tradjenta (Type 2 Diabetes) - Forecast and Market Analysis to 2022'. The ... through the use of combination therapies and novel branded drugs. Tradjenta (linagliptin) was developed by Boehringer Ingelheim and approved by the FDA ...

Jul, 2013 47 pages
Tofogliflozin (Type 2 Diabetes) - Forecast and Market Analysis to 2022 US$ 3,495.00

... Market Analysis to 2022 Summary GlobalData has released its new report, “Tofogliflozin (Type 2 Diabetes) - Forecast and Market Analysis to 2022”. The ... through the use of combination therapies and novel branded drugs. Tofogliflozin is an SGLT-2 inhibitor being investigated in Phase III clinical trials for ...

Jul, 2013 59 pages
Semaglutide (Type 2 Diabetes) - Forecast and Market Analysis to 2022 US$ 3,495.00

... and Market Analysis to 2022 Summary GlobalData has released its new report, “Semaglutide (Type 2 Diabetes) - Forecast and Market Analysis to 2022”. The ... ’ efforts to delay disease progression and reduce the costly burden of diabetic complications through the use of combination therapies and novel branded ...

Jul, 2013 60 pages
OpportunityAnalyzer: Diabetic Foot Ulcers - Opportunity Analysis and Forecast to 2017 US$ 5,995.00

OpportunityAnalyzer: Diabetic Foot Ulcers - Opportunity Analysis and Forecast to 2017 Summary Diabetic foot ulcers (DFUs) are a common complication of diabetes, and with the increasing prevalence of diabetes across all markets, the number of patients suffering from DFUs is also expected to rise. Despite ...

Oct, 2013 159 pages
MK-3102 (Type 2 Diabetes) - Forecast and Market Analysis to 2022 US$ 3,495.00

... and Market Analysis to 2022 Summary GlobalData has released its new report, “MK-3102 (Type 2 Diabetes) - Forecast and Market Analysis to 2022”. The type ... ’ efforts to delay disease progression and reduce the costly burden of diabetic complications through the use of combination therapies and novel branded ...

Jul, 2013 60 pages
LY2605541 (Type 2 Diabetes) - Forecast and Market Analysis to 2022 US$ 3,495.00

... and Market Analysis to 2022 Summary GlobalData has released its new report, “LY2605541 (Type 2 Diabetes) - Forecast and Market Analysis to 2022”. The ... ’ efforts to delay disease progression and reduce the costly burden of diabetic complications through the use of combination therapies and novel branded ...

Jul, 2013 59 pages
LY2409021 (Type 2 Diabetes) - Forecast and Market Analysis to 2022 US$ 3,495.00

... and Market Analysis to 2022 Summary GlobalData has released its new report, “LY2409021 (Type 2 Diabetes) - Forecast and Market Analysis to 2022”. The ... through the use of combination therapies and novel branded drugs. LY2409021 is a novel, first-in-class glucagon receptor antagonist being developed by Eli ...

Jul, 2013 60 pages
Ipragliflozin (Type 2 Diabetes) - Forecast and Market Analysis to 2022 US$ 3,495.00

... and Market Analysis to 2022 Summary GlobalData has released its new report, “Ipragliflozin (Type 2 Diabetes) - Forecast and Market Analysis to 2022”. The ... ’ efforts to delay disease progression and reduce the costly burden of diabetic complications through the use of combination therapies and novel branded ...

Jul, 2013 59 pages
Fasiglifam (Type 2 Diabetes) - Forecast and Market Analysis to 2022 US$ 3,495.00

... and Market Analysis to 2022 Summary GlobalData has released its new report, “Fasiglifam (Type 2 Diabetes) - Forecast and Market Analysis to 2022”. The ... ’ efforts to delay disease progression and reduce the costly burden of diabetic complications through the use of combination therapies and novel branded ...

Jul, 2013 61 pages
EpiCast Report: Diabetic Retinopathy - Epidemiology Forecast to 2022 US$ 3,995.00

EpiCast Report: Diabetic Retinopathy - Epidemiology Forecast to 2022 Summary Diabetic retinopathy is the principal cause of vision impairment in working-age adults throughout ... plans. Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for diabetic ...

Nov, 2013 50 pages
EpiCast Report: Diabetic Nephropathy - Epidemiology Forecast to 2022 US$ 3,995.00

EpiCast Report: Diabetic Nephropathy - Epidemiology Forecast to 2022 Summary With the increasing prevalence of diabetes around the world, diabetic nephropathy is the ... factors and common comorbidities for type 2 diabetes are also considered to be the same for diabetic nephropathy. The major risk factors for ...

Nov, 2013 39 pages
Empagliflozin (Type 2 Diabetes) - Forecast and Market Analysis to 2022 US$ 3,495.00

... and Market Analysis to 2022 Summary GlobalData has released its new report, “Empagliflozin (Type 2 Diabetes) - Forecast and Market Analysis to 2022”. The ... ’ efforts to delay disease progression and reduce the costly burden of diabetic complications through the use of combination therapies and novel branded ...

Jul, 2013 61 pages
Dulaglutide (Type 2 Diabetes) - Forecast and Market Analysis to 2022 US$ 3,495.00

... and Market Analysis to 2022 Summary GlobalData has released its new report, “Dulaglutide (Type 2 Diabetes) - Forecast and Market Analysis to 2022”. The ... ’ efforts to delay disease progression and reduce the costly burden of diabetic complications through the use of combination therapies and novel branded ...

Jul, 2013 63 pages
PharmaPoint: Type 2 Diabetes - US Drug Forecast and Market Analysis to 2022 US$ 4,995.00

... to 2022 Summary GlobalData has released its new Country report, “PharmaPoint: Type 2 Diabetes - US Drug Forecast and Market Analysis to 2022”. The type ... ’ efforts to delay disease progression and reduce the costly burden of diabetic complications through the use of combination therapies and novel branded ...

Jul, 2013 220 pages
PharmaPoint: Type 2 Diabetes - UK Drug Forecast and Market Analysis to 2022 US$ 4,995.00

... to 2022 Summary GlobalData has released its new Country report, “PharmaPoint: Type 2 Diabetes - UK Drug Forecast and Market Analysis to 2022”. The type ... ’ efforts to delay disease progression and reduce the costly burden of diabetic complications through the use of combination therapies and novel branded ...

Jul, 2013 230 pages
PharmaPoint: Type 2 Diabetes - Spain Drug Forecast and Market Analysis to 2022 US$ 4,995.00

... 2022 Summary GlobalData has released its new Country report, “PharmaPoint: Type 2 Diabetes - Spain Drug Forecast and Market Analysis to 2022”. The type ... ’ efforts to delay disease progression and reduce the costly burden of diabetic complications through the use of combination therapies and novel branded ...

Jul, 2013 227 pages
PharmaPoint: Type 2 Diabetes - Japan Drug Forecast and Market Analysis to 2022 US$ 4,995.00

... 2022 Summary GlobalData has released its new Country report, “PharmaPoint: Type 2 Diabetes - Japan Drug Forecast and Market Analysis to 2022”. The type ... ’ efforts to delay disease progression and reduce the costly burden of diabetic complications through the use of combination therapies and novel branded ...

Jul, 2013 236 pages
PharmaPoint: Type 2 Diabetes - Italy Drug Forecast and Market Analysis to 2022 US$ 4,995.00

... 2022 Summary GlobalData has released its new Country report, “PharmaPoint: Type 2 Diabetes - Italy Drug Forecast and Market Analysis to 2022”. The type ... ’ efforts to delay disease progression and reduce the costly burden of diabetic complications through the use of combination therapies and novel branded ...

Jul, 2013 227 pages
PharmaPoint: Type 2 Diabetes - India Drug Forecast and Market Analysis to 2022 US$ 4,995.00

... 2022 Summary GlobalData has released its new Country report, “PharmaPoint: Type 2 Diabetes - India Drug Forecast and Market Analysis to 2022”. The type ... diseases. This is now spilling over to other chronic diseases like diabetes. Recently, Merck's bid to prevent Indian drug maker Glenmark Pharmaceuticals ...

Jul, 2013 198 pages
PharmaPoint: Type 2 Diabetes - Germany Drug Forecast and Market Analysis to 2022 US$ 4,995.00

... to 2022 Summary GlobalData has released its new Country report, “PharmaPoint: Type 2 Diabetes - Germany Drug Forecast and Market Analysis to 2022”. The ... ’ efforts to delay disease progression and reduce the costly burden of diabetic complications through the use of combination therapies and novel branded ...

Jul, 2013 212 pages
PharmaPoint: Type 2 Diabetes - France Drug Forecast and Market Analysis to 2022 US$ 4,995.00

... 2022 Summary GlobalData has released its new Country report, “PharmaPoint: Type 2 Diabetes - France Drug Forecast and Market Analysis to 2022”. The type ... ’ efforts to delay disease progression and reduce the costly burden of diabetic complications through the use of combination therapies and novel branded ...

Jul, 2013 222 pages
PharmaPoint: Type 2 Diabetes - Current and Future Players US$ 2,995.00

... Players Summary GlobalData has released its pharma report, “PharmaPoint: Type 2 Diabetes - Current and Future Players”. The report is a vital source ... a high level view of the trends shaping and driving the Type 2 Diabetes Market Assess competitiveness of products in market by understanding the strengths ...

Jul, 2013 80 pages
PharmaPoint: Type 2 Diabetes - China Drug Forecast and Market Analysis to 2022 US$ 4,995.00

... Summary GlobalData has released its new Country report, “PharmaPoint: Type 2 Diabetes - China Drug Forecast and Market Analysis to 2022”. The ... , diagnosis, and treatment guidelines Detailed information on the key drugs in China including product description, safety and efficacy profiles as well as a SWOT ...

Jul, 2013 206 pages
PharmaPoint: Type 2 Diabetes - Brazil Drug Forecast and Market Analysis to 2022 US$ 4,995.00

... 2022 Summary GlobalData has released its new Country report, “PharmaPoint: Type 2 Diabetes - Brazil Drug Forecast and Market Analysis to 2022”. The type ... ’ efforts to delay disease progression and reduce the costly burden of diabetic complications through the use of combination therapies and novel branded ...

Jul, 2013 211 pages
Invokana (Type 2 Diabetes) - Forecast and Market Analysis to 2022 US$ 3,495.00

... and Market Analysis to 2022 Summary GlobalData has released its new report, “Invokana (Type 2 Diabetes) - Forecast and Market Analysis to 2022”. The ... branded drugs. On March 29, 2013, the FDA approved Johnson & Johnson’s Invokana (canagliflozin), the first-to-the-US-market SGLT-2 inhibitor for treatment ...

Jul, 2013 47 pages
Forxiga (Type 2 Diabetes) - Forecast and Market Analysis to 2022 US$ 3,495.00

... Market Analysis to 2022 Summary GlobalData has released its new report, “Forxiga (Type 2 Diabetes) - Forecast and Market Analysis to 2022”. The ... through the use of combination therapies and novel branded drugs. Forxiga (dapagliflozin) is the first-in-class selective SGLT-2 inhibitor, developed by Bristol ...

Jul, 2013 47 pages
Albiglutide (Type 2 Diabetes) - Forecast and Market Analysis to 2022 US$ 3,495.00

... and Market Analysis to 2022 Summary GlobalData has released its new report, “Albiglutide (Type 2 Diabetes) - Forecast and Market Analysis to 2022”. The ... ’ efforts to delay disease progression and reduce the costly burden of diabetic complications through the use of combination therapies and novel branded ...

Jul, 2013 62 pages
China Diabetes Market Outlook 2018 US$ 1,000.00

... to reach approximately US$ 4.6 Billion by 2018. In RNCOS’ latest report “China Diabetes Market Outlook 2018”, the country’s diabetes market has been segmented ... been extending their product portfolios in order to gain their own market shares. In the end, RNCOS concludes with a competitive analysis of major ...

Nov, 2013 50 pages
Type 2 Diabetes Therapeutics Market to 2019 - A Shifting Treatment Algorithm and Intensified Competition Expected to Drive Growth by 2019 US$ 3,500.00

... released its latest report for the pharmaceuticals industry, “Type 2 Diabetes Therapeutics Market to 2019 - A Shifting Treatment Algorithm and Intensified Competition ... drugs belonging to these newer classes are due to enter the market, and are expected to offer a moderate improvement in terms of efficacy and ...

Oct, 2013 123 pages
Diabetes - KOL Insight and Consensus Outlook Modules US$ 7,495.00

... term: battle lines are drawn The fundamental drivers of the global diabetes market are strong and continue to fuel growth. Rising levels ... comprehensive FirstWord research is available in two comprehensive modules: The KOL Insight: Diabetes module provides a complete review and is enhanced with exclusive ...

Feb, 2014 224 pages
1 2 3 4 >
Skip to top